Inspired by the anti-human immunodeficiency virus (HIV) activity of analogues of β-galactosylceramide (GalCer), a set of mono- and di-saccharide fatty acid esters were designed as GalCer mimetics and their binding to the V3 loop peptide of HIV-1 and anti-HIV activity evaluated. 1,1-linked Gal-Man and Glu-Man disaccharides with an ester on the Man subunit bound the V3 loop peptide and inhibited HIV infectivity in single round infection assays with the TZM-bl cell line. IC(50)'s were in the 50 μM range with no toxicity to the cells at concentrations up to 200 μM. These compounds appear to inhibit virus entry at early steps in viral infection since they were inactive if added post viral entry. Although these compounds were found to bind to the V3 loop peptide of gp120, it is not clear that this interaction is responsible for their anti-HIV activity because the relative binding affinity of closely related analogues did not correlate with their antiviral behavior. The low cytotoxicity of these 1,1-linked disaccharide fatty acid esters, combined with the easy accessibility to structurally diverse analogues make these molecules attractive leads for new topical anti-viral agents.
Inspired by the anti-human immunodeficiency virus (HIV) activity of analogues of β-pan class="Chemical">galactosylceramide (GalCer), a set of mono- and di-saccharide fatty acid esters were designed as GalCer mimetics and their binding to the V3 loop peptide of HIV-1 and anti-HIV activity evaluated. 1,1-linked Gal-Man and Glu-Mandisaccharides with an ester on the Man subunit bound the V3 loop peptide and inhibited HIV infectivity in single round infection assays with the TZM-bl cell line. IC(50)'s were in the 50 μM range with no toxicity to the cells at concentrations up to 200 μM. These compounds appear to inhibit virus entry at early steps in viral infection since they were inactive if added post viral entry. Although these compounds were found to bind to the V3 loop peptide of gp120, it is not clear that this interaction is responsible for their anti-HIV activity because the relative binding affinity of closely related analogues did not correlate with their antiviral behavior. The low cytotoxicity of these 1,1-linked disaccharide fatty acid esters, combined with the easy accessibility to structurally diverse analogues make these molecules attractive leads for new topical anti-viral agents.
Authors: Yue-Ling Wong; M Patricia Hubieki; Christopher L Curfman; Gustavo F Doncel; Travis C Dudding; Prashant S Savle; Richard D Gandour Journal: Bioorg Med Chem Date: 2002-11 Impact factor: 3.641
Authors: Nicole Lund; Donald R Branch; Murugespillai Mylvaganam; Davin Chark; Xue-Zhong Ma; Darinka Sakac; Beth Binnington; Jacques Fantini; Anu Puri; Robert Blumenthal; Clifford A Lingwood Journal: AIDS Date: 2006-02-14 Impact factor: 4.177
Authors: Katherine D McReynolds; Abhijit Bhat; John C Conboy; S Scott Saavedra; Jacquelyn Gervay-Hague Journal: Bioorg Med Chem Date: 2002-03 Impact factor: 3.641
Authors: Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal Journal: J Virol Date: 2012-02-15 Impact factor: 5.103